Products Research Area/Disease Metabolism CircuLex S100A7/Psoriasin ELISA Kit

CircuLex S100A7/Psoriasin ELISA Kit

CircuLex S100A7/Psoriasin ELISA Kit.

Specifications:

Description

The CycLex Research Product CircuLex S100A7/Psoriasin ELISA Kit is used for the quantitative measurement of human S100A7/Psoriasin in washing fluid from skin, nipple fluid, tissue culture medium and other biological samples probably including serum, plasma. It can be used for 96 Assays.

Target:	S100A7/Psoriasin
Product Type:	ELISA Kit
Size:	96 Assays
Application:	ELISA
Research Area / Disease:	Metabolism, Neuroscience
Sensitivity:	better than 0.12 ng/ml of sample.
Measurement Range:	Dilution factors need to be taken into consideration in calculating the human S100A7/Psoriasin concentration. Results exceeding human S100A7/Psoriasin level of 90 ng/ml should be repeated with diluted samples.
Regulatory Statement:	For Research Use Only. Not for use in diagnostic procedures.

Components

Microplate
10X Wash Buffer
Dilution Buffer
Human S100A7/Psoriasin Standard
HRP conjugated Detection Antibody
Substrate Reagent
Stop Solution

Citations

Cecchettini, Antonella, et al. “Phenotyping multiple subsets in Sjögren’s syndrome: a salivary proteomic SWATH-MS approach towards precision medicine.” Clinical proteomics 16.1 (2019): 1-11.
Alvendal, Cathrin, et al. “Expression of Psoriasin in Human Papillomavirus–Induced Cervical High-Grade Squamous Intraepithelial Lesions.” Journal of Lower Genital Tract Disease 23.1 (2019): 33-38.
Nienhouse V et al. Interplay between bladder microbiota and urinary antimicrobial peptides: mechanisms for human urinary tract infection risk and symptom severity. PLoS One. 9, e114185 (2014)
Jansen S et al. Expression and function of psoriasin (S100A7) and koebnerisin (S100A15) in the brain. Infect Immun. 81, 1788-97 (2013),
Salama RH et al. Psoriasin: a novel marker linked obesity with psoriasis. Dis Markers. 34, 33-9 (2013)

References

Madsen P, Rasmussen HH & Leffers H et al. Molecular cloning, occurrence, and expression of a novel partially secreted protein “psoriasin” that is highly up-regulated in psoriatic skin. J Invest Dermatol (1991) 97: 701–712.
Broome AM, Ryan D & Eckert RL. S100 protein subcellular localization during epidermal differentiation and psoriasis. J Histochem Cytochem (2003) 51: 675–685.
Hitomi J, Yamaguchi K & Kikuchi Y et al. A novel calcium-binding protein in amniotic fluid, CAAF1: Its molecular cloning and tissue distribution. J Cell Sci (1996) 109: 805–815.
Katz AB & Taichman LB. A partial catalog of proteins secreted by epidermal keratinocytes in culture. J Invest Dermatol (1999) 112: 818–821.
Karimi-Busheri F, Marcoux Y & Tredget EE et al. Expression of a releasable form of annexin II by human keratinocytes. J Cell Biochem (2002) 86: 737–747.
Hoffmann HJ, Olsen E & Etzerodt M et al. Psoriasin binds calcium and is upregulated by calcium to levels that resemble those observed in normal skin. J Invest Dermatol (1994) 103: 370–375.
Jinquan T, Vorum H & Larsen CG et al. Psoriasin: A novel chemotactic protein. J Invest Dermatol (1996) 107: 5–10.
Algermissen B, Sitzmann J, LeMotte P & Czarnetzki B. Differential expression of CRABP II, psoriasin and cytokeratin 1 mRNA in human skin diseases. Arch Dermatol Res (1996) 288: 426–430.
Alowami S, Qing G & Emberley E et al. Psoriasin (S100A7) expression is altered during skin tumorigenesis. BMC Dermatol (2003) 3: 1.
Glaser, R.; Harder, J.; Lange, H.; Bartels, J.; Christophers, E.; Schroder, J.-M. Antimicrobial psoriasin (S100A7) protects human skin from Escherichia coli infection. Nature Immun. (2005) 6: 57-64